Type 2 Diabetes — Deal Benchmarks & Valuation
Market Analysis
Type 2 Diabetes is one of the most actively transacted indications in metabolic licensing. Phase 2 deals for type 2 diabetes carry a median total deal value of $4.0B, with upfront payments ranging from $444M to $1.2B. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.
Milestone structures for type 2 diabetes deals allocate $564M to development milestones, $690M to regulatory milestones, and $1.9B to commercial milestones. Royalty rates range from 15.5% to 28.3% at the base tier, with tiered escalation reaching 19.5%-32.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for type 2 diabetes licensing?
What royalty rates are standard for type 2 diabetes deals?
How are type 2 diabetes deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.